Therapeutical evaluation of bevacizumab application in relapsed pterygium

Detalhes bibliográficos
Autor(a) principal: Abrahão,Mayara Martins
Data de Publicação: 2017
Outros Autores: Teixeira,Leonardo Pinheiro, Mendanha,Denise Borges de Andrade, Campos,Luana Miranda, Vilar,Mateus Martins Cortez, Nassaralla Junior,João Jorge
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232
Resumo: Abstract Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly on the tenth and thirtieth days after the application, seeking to compare with the exam previously made, being it realized with the other two groups, in which Group 2 (4 patients) received 0.2 ml of Bevacizumab and the Group 3 (3 patients) received 1 ml of the placebo injection. Results: In this study, eleven eyes of eleven patients were evaluated. Among these patients, 7 were women (63.6%) and 4 men (36.4%). There was a variation in the cylindrical diopter after the treatment with a dose of 0.1 ml of bevaciumab during the evaluation on the thirtieth day. Whereas the cylindrical shaft had a significantly larger modification after the application of 0.2 ml. Regarding the spherical diopter variation, there were modifications in the 3 groups. The keratometry varied in the 3 groups, mostly after the thirtieth day of evaluation. In relation to symptomatology, it was observed a reduction in the subjective evaluation of the eye burning sensation, the prurience mentioned by the patient and a reduction of the hyperemia biomicroscopy evaluation. Conclusion: In bevacizumab application in the recurrent pterygium treatment, there is modification of the spherical and cylindrical parameters of refraction, besides the changes in keratometry and the reduction of the symptomatology.
id SBO-1_6cdbee4a1eb5e4f7ce4f77740f16d484
oai_identifier_str oai:scielo:S0034-72802017000500232
network_acronym_str SBO-1
network_name_str Revista Brasileira de Oftalmologia (Online)
repository_id_str
spelling Therapeutical evaluation of bevacizumab application in relapsed pterygiumPterygium/drug therapyBevacizumab/therapeutic useVisual acuityRefractionAbstract Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly on the tenth and thirtieth days after the application, seeking to compare with the exam previously made, being it realized with the other two groups, in which Group 2 (4 patients) received 0.2 ml of Bevacizumab and the Group 3 (3 patients) received 1 ml of the placebo injection. Results: In this study, eleven eyes of eleven patients were evaluated. Among these patients, 7 were women (63.6%) and 4 men (36.4%). There was a variation in the cylindrical diopter after the treatment with a dose of 0.1 ml of bevaciumab during the evaluation on the thirtieth day. Whereas the cylindrical shaft had a significantly larger modification after the application of 0.2 ml. Regarding the spherical diopter variation, there were modifications in the 3 groups. The keratometry varied in the 3 groups, mostly after the thirtieth day of evaluation. In relation to symptomatology, it was observed a reduction in the subjective evaluation of the eye burning sensation, the prurience mentioned by the patient and a reduction of the hyperemia biomicroscopy evaluation. Conclusion: In bevacizumab application in the recurrent pterygium treatment, there is modification of the spherical and cylindrical parameters of refraction, besides the changes in keratometry and the reduction of the symptomatology.Sociedade Brasileira de Oftalmologia2017-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232Revista Brasileira de Oftalmologia v.76 n.5 2017reponame:Revista Brasileira de Oftalmologia (Online)instname:Sociedade Brasileira de Oftalmologia (SBO)instacron:SBO10.5935/0034-7280.20170048info:eu-repo/semantics/openAccessAbrahão,Mayara MartinsTeixeira,Leonardo PinheiroMendanha,Denise Borges de AndradeCampos,Luana MirandaVilar,Mateus Martins CortezNassaralla Junior,João Jorgeeng2018-02-20T00:00:00Zoai:scielo:S0034-72802017000500232Revistahttps://rbo.emnuvens.com.br/rbo/indexhttps://old.scielo.br/oai/scielo-oai.phpsob@sboportal.org.br||rbo@sboportal.org.br1982-85510034-7280opendoar:2018-02-20T00:00Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)false
dc.title.none.fl_str_mv Therapeutical evaluation of bevacizumab application in relapsed pterygium
title Therapeutical evaluation of bevacizumab application in relapsed pterygium
spellingShingle Therapeutical evaluation of bevacizumab application in relapsed pterygium
Abrahão,Mayara Martins
Pterygium/drug therapy
Bevacizumab/therapeutic use
Visual acuity
Refraction
title_short Therapeutical evaluation of bevacizumab application in relapsed pterygium
title_full Therapeutical evaluation of bevacizumab application in relapsed pterygium
title_fullStr Therapeutical evaluation of bevacizumab application in relapsed pterygium
title_full_unstemmed Therapeutical evaluation of bevacizumab application in relapsed pterygium
title_sort Therapeutical evaluation of bevacizumab application in relapsed pterygium
author Abrahão,Mayara Martins
author_facet Abrahão,Mayara Martins
Teixeira,Leonardo Pinheiro
Mendanha,Denise Borges de Andrade
Campos,Luana Miranda
Vilar,Mateus Martins Cortez
Nassaralla Junior,João Jorge
author_role author
author2 Teixeira,Leonardo Pinheiro
Mendanha,Denise Borges de Andrade
Campos,Luana Miranda
Vilar,Mateus Martins Cortez
Nassaralla Junior,João Jorge
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Abrahão,Mayara Martins
Teixeira,Leonardo Pinheiro
Mendanha,Denise Borges de Andrade
Campos,Luana Miranda
Vilar,Mateus Martins Cortez
Nassaralla Junior,João Jorge
dc.subject.por.fl_str_mv Pterygium/drug therapy
Bevacizumab/therapeutic use
Visual acuity
Refraction
topic Pterygium/drug therapy
Bevacizumab/therapeutic use
Visual acuity
Refraction
description Abstract Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly on the tenth and thirtieth days after the application, seeking to compare with the exam previously made, being it realized with the other two groups, in which Group 2 (4 patients) received 0.2 ml of Bevacizumab and the Group 3 (3 patients) received 1 ml of the placebo injection. Results: In this study, eleven eyes of eleven patients were evaluated. Among these patients, 7 were women (63.6%) and 4 men (36.4%). There was a variation in the cylindrical diopter after the treatment with a dose of 0.1 ml of bevaciumab during the evaluation on the thirtieth day. Whereas the cylindrical shaft had a significantly larger modification after the application of 0.2 ml. Regarding the spherical diopter variation, there were modifications in the 3 groups. The keratometry varied in the 3 groups, mostly after the thirtieth day of evaluation. In relation to symptomatology, it was observed a reduction in the subjective evaluation of the eye burning sensation, the prurience mentioned by the patient and a reduction of the hyperemia biomicroscopy evaluation. Conclusion: In bevacizumab application in the recurrent pterygium treatment, there is modification of the spherical and cylindrical parameters of refraction, besides the changes in keratometry and the reduction of the symptomatology.
publishDate 2017
dc.date.none.fl_str_mv 2017-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802017000500232
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0034-7280.20170048
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Oftalmologia
publisher.none.fl_str_mv Sociedade Brasileira de Oftalmologia
dc.source.none.fl_str_mv Revista Brasileira de Oftalmologia v.76 n.5 2017
reponame:Revista Brasileira de Oftalmologia (Online)
instname:Sociedade Brasileira de Oftalmologia (SBO)
instacron:SBO
instname_str Sociedade Brasileira de Oftalmologia (SBO)
instacron_str SBO
institution SBO
reponame_str Revista Brasileira de Oftalmologia (Online)
collection Revista Brasileira de Oftalmologia (Online)
repository.name.fl_str_mv Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)
repository.mail.fl_str_mv sob@sboportal.org.br||rbo@sboportal.org.br
_version_ 1752122338172731392